Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187986 | 0.79 | CASP3 (0.41) | TDP1PDGFRBPDGFRAPSMB5PPARA | |
| SCHEMBL10382864 | 0.76 | PPARA (0.39) | TDP1PDGFRBPDGFRAPPARACASP3 | |
| SCHEMBL20188885 | 0.73 | CASP3 (0.47) | TDP1PDGFRBPDGFRAPSMB5CASP3 | |
| SCHEMBL15260158 | 0.71 | PIK3CA (0.39) | CDK2 | |
| SCHEMBL18015411 | 0.69 | TDP1 (0.53) | TDP1PSMB5CASP3SENP8SENP7 | |
| SCHEMBL21614488 | 0.68 | QDPR (0.45) | — | |
| SCHEMBL604266 | 0.68 | TYMP (0.40) | TDP1PDGFRBPDGFRAPSMB5PPARA | |
| SCHEMBL15048839 | 0.68 | TYMP (0.40) | TDP1PDGFRBPDGFRAPSMB5PPARA | |
| SCHEMBL21055801 | 0.67 | TDP1 (0.50) | TDP1PDGFRBPDGFRAPPARACASP3 | |
| SCHEMBL3583190 | 0.67 | HTR2C (0.50) | PDGFRBPDGFRAPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137547-B | Heterocyclic compounds useful as TNF alpha modulators | 百时美施贵宝公司 | 2021-11-12 | — | — | CN | disclosed |
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3331871-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | Bristol-Myers Squibb Company (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017023905-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865191-B2 | Heterocyclic compounds useful as modulators of TNF alpha | TNF, TNFRSF9, TNFRSF1A | TDP1 3340/4885PDGFRB 1784/4885PDGFRA 2503/4885 |
| US-20180222883-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | TNF, TNFRSF9, TNFRSF1A | TDP1 3340/4885PDGFRB 1784/4885PDGFRA 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.